Home Seeking Alpha: Stock Market Analysis Anavex: Additional P2b/3 Alzheimer’s Trial Data Raises Additional Questions (NASDAQ:AVXL)

Anavex: Additional P2b/3 Alzheimer’s Trial Data Raises Additional Questions (NASDAQ:AVXL)

by Hataf Finance
18 minutes read


On Thursday, September 14, Anavex Life Sciences (NASDAQ:AVXL), a clinical-stage biopharmaceutical company which develops small molecule drugs for neurodegenerative diseases such as Alzheimer’s disease (AD), Parkinson’s disease, Rett syndrome etc. announced additional data from their phase 2b/3 Alzheimer’s


On Safety, this is what the company reported on December 1, 2022:

“ANAVEX®2-73 (blarcamesine) was generally safe and well tolerated. The incidence of treatment emergent adverse events (TEAEs) was similar in the active and placebo arms with dizziness being the most common TEAE. TEAEs ≥7.5% threshold were predominantly mild or moderate. No clinically significant changes in vital signs, laboratory values and ECG parameters in active and placebo arms were observed. Safety findings in the study were consistent with the known safety profile of ANAVEX®2-73.” (bold emphasis added)

On safety, this is what the company reported on September 14, 2023:

“In the respective safety population, common treatment-emergent adverse events included dizziness, which was transient and mostly mild to moderate in severity, and occurred in 120 participants (35.8%) during titration and in 76 participants (25.2%) during maintenance with blarcamesine and 10 (6.0%) during titration and 9 (5.6%) during maintenance with placebo.”


During titration


during maintenance

Treatment groups35.8%25.2%

Source link

You may also like

Leave a Comment

Hataf News Unleash the Power of Financial Insight! Stay ahead of the game with our dynamic platform, delivering real-time updates, expert analysis, and exclusive market trends. Empower your financial decisions with Hataf News and make your wealth thrive!

Hataf News, A Media Company – All Right Reserved. Designed and Developed by Hataf Tech

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More